Editorial on Market Analysis for Experimental Stroke and Translational MedicineAuthor(s): Stefan Farsky
The cardiovascular market research reports by iData cover Interventional Cardiology, Cardiac Surgery, Cardiac Rhythm Management and the Electrophysiology market. The fastest growing segments within interventional cardiology are expected to be driven by new technologies, such as CTO crossers, FFR guidewires and OCT catheters. The vascular access market will grow due to a combination of increasing patient population and the shift towards technologically advanced devices that will continue to gain market share at the expense of older, less expensive devices. Factors like technological advancement, a growing aging population, and people affected by diabetes, high blood pressure are favouring the market. On the other hand, increasing health expenditure, cardiovascular diseases and increasing tobacco users are supplying the market. Throughout this research series, iData has covered several countries in great detail. Each country may be purchased as a stand-alone report, tailoring the data to your needs. iData Research has an ever-expanding medical market intelligence library consisting of focused, in-depth, accurate, and exclusive research you will not find anywhere else. Our highly qualified team of industry analysts follow a structured and independent research methodology designed to provide the most valuable return on actionable market data in the world. Similar to other medical device markets, the interventional cardiology market has been experiencing a period of consolidation in recent years. Large competitors are either entering the overall market or expanding their reach by entering new segments through strategic mergers and acquisitions. One trend that has risen as a result of consolidation is the bundling of devices at a discount. Bundling is driven by unfavorable reimbursement conditions and larger competitors who have a wide variety of devices to offer across the interventional cardiology market and are able to negotiate more cost-effective contracts with hospitals and labs. As a result competitive pressure is expected to contribute to declines in prices across the majority of segments in the market.